Choong-wae Pharm to conduct local Phase III trials for mitigilinide, novel blood glucose lowering...
Following the recent NDA approval of mitigilinide, a novel short-acting insulin secretagogue to suppress postprandial hyperglycemia, filed by Kissei Pharmaceutical Co. in Japan, Choong-wae P...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
